Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. To explore a possible connection between AKT and FAS, immunohistochemical analyses were conducted on an ovarian cancer tissue microarray, which revealed a significant correlation between phosphorylated AKT (phospho-AKT) and expression of FAS. To investigate the relationship between phospho-AKT and FAS in vitro, a variety of experiments employing a specific phosphatidylinositol 3-OH kinase (PI3K) inhibitor (LY294002), inducible PTEN expression in PTEN-null cells, or AKT1 siRNA demonstrated that phosphatidylinositol-3 kinase (PI3K)/AKT signaling modulates FAS expression. In contrast, inhibition of FAS activity by the drug C75 resulted in downregulation of phospho-AKT and increased cell death. To explore the functional relationship between phospho-AKT and FAS, we used SKOV3, C200, and OVCAR10 ovarian carcinoma cells, which have constitutively active AKT, and OVCAR5 cells, which have very low basal phospho-AKT levels. Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. To investigate the relationship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperitoneally with SKOV3 cells were treated with C75. Growth of SKOV3 xenografts was markedly inhibited by C75. Analysis of the levels of phospho-AKT and FAS in C75-treated tumors revealed concordant downregulation of phospho-AKT and FAS. Collectively, our findings are consistent with a working model in which AKT activation regulates FAS expression, at least in part, whereas FAS activity modulates AKT activation.
Introduction
Ovarian cancer is the most common cause of death from gynecologic cancer among women in the United States. Recurrent molecular genetic alterations seen in ovarian cancer include MYC amplification, TP53 and KRAS mutations, overexpression of HER2/neu, and germline mutations of BRCA1 and BRCA2 (Aunoble et al., 2000) . In addition, phosphatidylinositol 3-OH kinase (PI3K) amplification has been reported in some ovarian carcinomas and ovarian cancer cell lines and is accompanied by increased PI3K activity (Shayesteh et al., 1999; Philp et al., 2001) . We previously demonstrated amplification and/or overexpression of the AKT2 oncogene in human ovarian cancers (Cheng et al., 1992) , and AKT2 and AKT1 kinases are frequently activated in primary ovarian carcinomas (Yuan et al., 2000; Sun et al., 2001) . Numerous studies have established that AKT activation promotes cell survival and enhances tumor cell growth and invasiveness (Datta et al., 1999; Testa and Bellacosa, 2001) . Moreover, active AKT has been shown to confer resistance to chemotherapy and radiation in cell lines derived from a variety of tumor types (Ng et al., 2000; Page et al., 2000; Hu et al., 2002) , and LY294002, a potent inhibitor of the PI3K/AKT pathway, inhibits growth of ovarian carcinoma cells in culture or as xenografts in nude mice (Hu et al., 2002) .
Fatty acid synthase (FAS) is a multifunctional metabolic enzyme that catalyses the terminal steps in the synthesis of long-chain saturated fatty acids. The production of fatty acids supports membrane synthesis in proliferating cells (Jackowski et al., 2000) . In normal cells, FAS is expressed at low levels due to the presence of abundant amounts of dietary lipids. However, increased levels of FAS are found in a wide array of solid tumors including carcinomas of the breast (Alo et al., 1996) , prostate (Epstein et al., 1995) , ovary (Gansler et al., 1997; Alo et al., 2000) , stomach (Kusakabe et al., 2002) , and lung (Piyathilake et al., 2000) , as well as in mesotheliomas (Gabrielson et al., 2001) , retinoblastomas (Camassei et al., 2003a) and nephroblastomas (Camassei et al., 2003b) . Overexpression of FAS appears to occur very early in cancer development and is more pronounced in clinically aggressive cancers (Gansler et al., 1997) . Inhibition of FAS activity preferentially inhibits tumor cell growth and induces apoptosis in breast cancer (Pizer et al., 1996a; Pizer et al., 1998) , prostate cancer (Pizer et al., 2001; De Schrijver et al., 2003) , and mesothelioma cells (Gabrielson et al., 2001 ). FAS appears to provide a selective proliferative advantage; thus, FAS has become a promising target for anticancer drug development.
PI3K/AKT signaling has been implicated in the regulation of FAS expression in breast cancer cells (Yang et al., 2002) , prostate cancer cells (Van de Sande et al., 2002) , and adipocyte/3T3 cells (Wang and Sul, 1998) . However, to date, a connection between downregulation of AKT expression and decreased FAS protein has not been documented, nor has it been shown that inhibition of FAS activity can inhibit AKT activation. In this report, we address the relationship between AKT and FAS in human cancer cells. We show that PI3K/AKT signaling regulates FAS expression, based on in vitro studies employing a variety of experimental tools including a specific PI3K inhibitor, a PTEN-deficient cell line stably transfected with an inducible PTEN construct, and AKT1 siRNA. In addition, inhibition of FAS activity by the drug C75 resulted in downregulation of phospho (active)-AKT and increased apoptosis. Based on these findings, we propose a positive feedback loop between AKT activation and FAS expression.
Results
To investigate the relationship between increased AKT activity and overexpression of FAS in human ovarian carcinomas, we performed immunohistochemical analyses of phosphorylated AKT (phospho-AKT) (Ser473) and FAS on an ovarian cancer tissue microarray. We found that 21 of 31 (68%) tumor specimens expressed elevated levels of phospho-AKT, and 25 of 31 (80%) expressed FAS (Table 1 ). All 21 cases with elevated phospho-AKT also expressed FAS (Po0.001, Fisher's exact test; Po0.0001, Jonckheere-Terpstra test). Among these, six with highest FAS staining also stained most intensely for phospho-AKT. Four tumors that expressed FAS did not show elevated staining for phospho-AKT. Six tumors were negative for both phospho-AKT and FAS protein. Figure 1 depicts serial sections of two representative tumors with intense staining for both phospho-AKT and FAS in tumor cells but not in adjacent stromal tissues. Collectively, these data indicate a significant correlation between AKT activation and FAS expression in this series of ovarian carcinomas.
Since phospho-AKT was present in most FASpositive ovarian carcinoma specimens, the presence of phospho-AKT may contribute to the expression of FAS in this subset of tumors. To test this hypothesis, we used several ovarian cancer cell lines that, under serum starvation conditions, exhibit constitutively active AKT (phospho-AKT), to determine if phospho-AKT affects FAS expression. First, serum-starved SKOV3 cells were treated with different concentrations of LY294002. As shown in Figure 2a , FAS protein levels as well as phospho-AKT levels decreased significantly after treatment with LY294002 in a dose-dependent manner. Similar to SKOV3 cells, FAS protein levels in OVCAR10 cells also decreased after treatment with LY294002 ( Figure 2b ). However, LY294002 treatment did not result in a significant decrease of FAS protein levels in OVCAR4 and OVCAR5 cells, which do not exhibit constitutively active AKT under serum starvation conditions (data not shown). Next, we used an endometrial carcinoma cell line (IT-3015) derived from PTEN-null Ishikawa cells. IT-3015 is engineered to express PTEN in a tetracycline-dependent manner. When PTEN expression was induced by the tetracycline analog doxycycline, both phospho-AKT and FAS levels decreased (Figure 2c ). To confirm that the effects of doxycycline on FAS expression are due to PTEN induction and not doxycycline treatment alone, parental Ishikawa cells were treated with doxycycline for 24 and 48 h, and no changes in phospho-AKT and FAS levels were observed at either time point (data not shown). To further explore the role of AKT in regulating FAS expression, we used HEK293 cells, which have constitutively active AKT and high transfection efficiency. By using AKT1 and AKT2 isoform-specific antibodies, we found that AKT1 is the predominant AKT isoform in 293 cells (data not shown). AKT1 siRNA was introduced into HEK293 cells, which resulted in a 60% reduction in AKT1 protein expression levels and a 50% reduction in FAS expression at 60 h post-transfection (Figure 2d ). AKT2 levels were not affected by AKT1 siRNA (Figure 2d ). To our knowledge, this is the first demonstration that downregulation of AKT1 leads to decreased expression of FAS. Collectively, the data summarized above indicate that PI3K/AKT signaling regulates FAS expression, and that AKT is a regulator of FAS expression.
Since the mitogen-activated protein kinase (MAPK) pathway has been shown to be involved in H-rasmediated upregulation of FAS expression in breast carcinoma cells (Yang et al., 2002) , we tested whether the MAPK pathway is also involved in the regulation of FAS expression in SKOV3 cells. Treatment of SKOV3 cells with the MAPK inhibitor PD 98059 did not alter FAS protein levels (data not shown), which indicates that the MAPK pathway is not involved in the regulation of FAS expression in this cell line.
To determine if FAS inhibition induces cell death in ovarian cancer cells, SKOV3, C200, and OVCAR10, each of which exhibits constitutively active AKT under serum starvation conditions, were treated with cerulenin, a naturally occurring FAS inhibitor (D'Agnolo et al., 1973) . Cerulenin at a concentration of 3 mg/ml induced cell death in SKOV3, C200, and OVCAR10 cells, but the amount of cell death differed among the cell lines (Figure 3a , d, and e). SKOV3 cells, which have the highest phospho-AKT levels, were the most sensitive to cerulenin, suggesting that endogenous AKT activity may be predictive of sensitivity to FAS inhibition. Similarly, Brognard et al. (2001) have demonstrated that lung cancer cell lines with constitutively active AKT are highly sensitive to chemotherapeutic drugs and radiation. As expected, treatment of ovarian carcinoma cells with the PI3K inhibitor LY294002 abolished AKT activity, consistent with AKT activation being PI3K-dependent. A marked increase in cerulenin-induced apoptosis was observed when LY294002 and cerulenin were added simultaneously in ovarian carcinoma cells with constitutively active AKT (SKOV3, C200, and OVCAR10) (Figure 3a , d, and e). In contrast, cerulenin at 3 mg/ml did not induce apoptosis in ovarian carcinoma cells without constitutively active AKT (OVCAR5), and no increase in cerulenin-induced apoptosis was observed when combining cerulenin with LY294002 in OVCAR5 cells (Figure 4a ). To exclude the possibility that the additive effects of LY294002 and cerulenin correlate with additive decrease in FAS level, we examined the levels of FAS expression after treatment of SKOV3 cells for 48 h with cerulenin or LY294002 alone, or with a combination of cerulenin and LY294002. As shown in Figure 3b , cerulenin alone did not decrease FAS protein levels. In contrast, LY294002 treatment resulted in decreased FAS expression, but no further decrease was observed when cerulenin and LY294002 were combined. In addition, to confirm that apoptosis occurred in SKOV3 cells treated with cerulenin or LY294002 alone, or with a combination of cerulenin and LY294002, immunoblot analysis was performed to determine the levels of active caspase-3. As shown in Figure 3c , active caspase-3 was induced by and FAS protein levels, but not AKT2 protein levels. HEK293 cells were transfected with AKT1 siRNA or control siRNA. At 60 h after transfection, whole cell lysates were prepared and subjected to Western blot analysis treatment with either cerulenin or LY294002 and was further increased when LY294002 and cerulenin were combined.
Next, we tested the effect of C75, a synthetic, chemically stable FAS inhibitor , on SKOV3 and OVCAR5 cells. We found that C75-induced apoptosis was significantly increased by inhibition of PI3K/AKT signaling in SKOV3 cells (Figure 3f ), but not in OVCAR5 cells (Figure 4b ). These results indicate that PI3K/AKT inhibition increases FAS inhibitor-induced apoptosis in cells with constitutively active AKT.
Fatty acids synthesized by FAS are incorporated into membrane phospholipids. Inhibition of FAS by C75 or FAS siRNA results in decreased phospholipid content in the membrane . Since activation of AKT relies on membrane phospholipids, we next tested if inhibition of FAS activity affects AKT activation. SKOV3 cells were serum-starved overnight and treated with C75 for 6, 12, and 24 h. C75 treatment resulted in markedly decreased levels of phospho-AKT at 12 h, and this was sustained to 24 h (Figure 5a ). Total AKT levels remained unchanged following treatment with C75. Phospho-AKT levels could also be downregulated by cerulenin treatment (Figure 5b ). In order to show that the decrease of phospho-AKT is not due to cytotoxicity of C75, we counted viable cells by Trypan blue exclusion assay. The percentage of viable cells at 12 h (93%71.83) and 24 h (95%70.95) post-C75 treatment did not differ from that observed in control cells (94%71.93). In addition, we did not observe any active caspase-3 or cleaved PARP product at 12 or 24 h post-treatment with C75 (data not shown). Collectively, these findings indicate that the C75-induced decrease in phospho-AKT is not due to general cytotoxicity. Cerulenin has previously been shown to inhibit tumor progression, including formation of ascites in an ovarian cancer xenograft model (Pizer et al., 1996b) . To test the effect of the newer synthetic FAS inhibitor C75 on SKOV3 xenografts in female severe combined immunodeficient (SCID) mice, individual animals were injected intraperitoneally (i.p.) with 5 Â 10 6 SKOV3 cells. After 1 week, mice were treated with C75 at a weekly dose of 20 mg/kg, or with 5% DMSO in PBS as a vehicle control. After 4 weeks of treatment, mice were killed and the tumors were collected. In addition to a large primary tumor, each vehicle-treated mouse developed multiple tumor nodules attached to the spleen, liver, or pancreas (mean number, 4.671.6 tumors per mouse). However, most of the C75-treated mice developed only a single visible tumor (Figure 6a) , which was usually located immediately below the stomach. C75-treated mice exhibited a 50% reduction in total tumor weight compared to vehicle-treated mice (Figure 6b ).
Since C75 treatment induced a reduction in phospho-AKT levels in SKOV3 cells in vitro, we tested whether treatment with C75 resulted in reduced phospho-AKT levels in vivo. We analysed phospho-AKT and FAS levels in primary tumors derived from vehicle-treated mice and tumors from C75-treated mice by Western blot analysis. Markedly decreased levels of both phospho-AKT and FAS were observed in four of six C75-treated tumors (Figure 6c ). Densitometric analysis revealed that the overall phospho-AKT and FAS expression levels observed in the six C75-treated tumors were significantly lower than in the control tumors. In two tumors, phospho-AKT and FAS levels did not decrease. We speculate that these two tumors acquired additional genetic or epigenetic changes during the numerous generations required for tumor formation, which may have rendered them insensitive to C75. Despite this discrepancy, it is notable that the amount of phospho-AKT was concordant with the level of FAS expression in all six tumors. In order to show that the decrease in phospho-AKT and FAS levels was not due to loss of tumor tissue through necrosis, all tumors were evaluated histologically. We did not observe any difference in the extent of necrosis between control and C75-treated tumors.
Finally, it is noteworthy that animals treated with C75 did exhibit weight loss. Similar to previous studies with other xenograft models, roughly a 15% reduction in body weight was observed in C75-treated mice (Figure 6d ). 
Discussion
Our studies indicate that there is a positive feedback regulation between AKT activation and FAS expression in ovarian carcinoma cells grown in vitro, and this is supported by a high correlation between AKT activation and FAS expression in primary ovarian carcinoma specimens. AKT activation appears to regulate FAS expression, at least in part, whereas fatty acids synthesized by FAS are incorporated into membrane phospholipids, which are mediators of AKT activation. Overexpression of FAS has been previously reported in a wide variety of human tumors. The close correlation between FAS expression and AKT activation in our series of ovarian carcinomas suggests that AKT plays an important role in regulating FAS expression in ovarian cancer. Our in vitro experiments with SKOV3 and OVCAR10 cells indicate that inhibition of PI3K/AKT signaling results in decreased expression of FAS. When PTEN expression was induced in PTEN-null IT-3015 cells, FAS and phospho-AKT levels decreased coordinately; in addition, when expression of AKT1 was knocked down about 60% in HEK293 cells after AKT1 siRNA transfection, we observed a 50% decrease in FAS levels. These several lines of evidence indicate that AKT activity modulates FAS expression. The data are consistent with previous reports showing that PI3K signaling regulates FAS expression in prostate cancer cells, breast cancer cells, and 3T3 adipocytes (Wang and Sul, 1998; Van de Sande et al., 2002; Yang et al., 2002) . AKT has been studied extensively during the past decade, and one of its main functions is to promote cell survival (Datta et al., 1999) . Cancer cells with constitutively active AKT may have a dependence on AKT activity for survival, and recent studies have demonstrated that inhibition of PI3K/AKT signaling can sensitize cancer cells to apoptosis induced by chemotherapeutic drugs or radiation (Ng et al., 2000; Page et al., 2000; Brognard et al., 2001; Clark et al., 2002; Hu et al., 2002; Schmidt et al., 2002; Jin et al., 2003; Knuefermann et al., 2003) . We found that LY294002 enhances C75-and cerulenin-induced apoptosis in cell lines exhibiting constitutively active AKT. FAS inhibition results in downregulation of phospho-AKT levels (Figure 4) , and LY294002 treatment may further decrease the levels of phospho-AKT, thus increasing FAS inhibitor-induced cell death in cells with constitutively active AKT.
Inhibition of FAS activity by either cerulenin or C75 downregulates phospho-AKT production. Regarding the specificity of C75 as a FAS inhibitor, recent work has shown that C75 affects two cellular processes. First, it inhibits fatty acid synthesis through slowbinding inhibition of FAS. Second, it increases fatty acid oxidation through increasing the activity of carnitine palmitoyltransferase-1 (CPT-1). Two recent publications (Thupari et al., 2002; Zhou et al., 2003) showed that FAS inhibition, not increased fatty acid oxidation, is responsible for C75's proapoptotic effects in human cancer cells. Etomoxir, an irreversible inhibitor of CPT-1, was not apoptotic to cancer cells, and it did not rescue cells from C75. These data implied that fatty acid oxidation is not involved in the mechanism of cytotoxicity of C75. Furthermore, C273, an oxidized form of C75, which does not inhibit FAS, is nontoxic to human cancer cells.
The mechanism(s) by which FAS inhibitors decrease AKT activity is not clear. One possible explanation is that FAS inhibition may cause an imbalance in membrane phospholipid levels, which may result in decreased AKT membrane localization and activation. This is supported by several lines of evidence. Firstly, lipid rafts are membrane microdomains, which serve as platforms for cell signaling (Sargiacomo et al., 1993) , and recent studies have revealed a connection between lipid rafts, AKT, and FAS. When rafts are disrupted, AKT phosphorylation is inhibited and cell survival is reduced (Hill et al., 2002; Zhuang et al., 2002) . Secondly, constitutively active AKT serine 473 kinase activity has been found in plasma membrane rafts, implicating a role for lipid rafts in AKT signaling (Hill et al., 2002) . Finally, it has been shown that FAS drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomain-raft aggregates . Moreover, RNA interference-mediated silencing of FAS inhibits growth and induces apoptosis of LNCaP prostate cancer cells . Since FAS plays a critical role in membrane raft phospholipid synthesis, a decrease in phospholipid levels would likely impair AKT activation. Our in vitro and in vivo data indicate that FAS inhibition indeed results in decreased AKT activity. However, other possibilities, including inhibition of PI3K or activation of PTEN or protein phosphatase-2A (Resjo et al., 2002) by lipid intermediates that accumulate following FAS inhibition, may also contribute to the decreased levels of phospho-AKT. Our in vivo studies of the effect of C75 on SKOV3 tumor growth in a murine xenograft model are consistent with results obtained with breast cancer and mesothelioma xenograft models Gabrielson et al., 2001) . In addition to an overall significant inhibition of SKOV3 tumor growth, Western blot analysis of tumors showed decreased AKT activity in most C75-treated mice, concordant with reduced FAS protein levels. Thus, FAS inhibition may have significant promise as a therapeutic approach in human ovarian cancer. In summary, data presented here demonstrate a significant correlation between the expression of FAS and active AKT in ovarian cancer and indicate that inhibition of PI3K/AKT signaling increases sensitivity to FAS inhibitor-induced apoptosis in ovarian carcinoma cells with constitutively active AKT. Our findings are consistent with a working model in which AKT activation regulates FAS expression, at least in part, whereas FAS activity modulates AKT activation. Furthermore, these data suggest that AKT activity and FAS expression are useful biomarkers in ovarian cancer and may serve as important targets for therapeutic invention in this disease.
Materials and methods

Cell culture
Five ovarian cancer cell lines were used: SKOV3, C200, a cisplatin-resistant ovarian cancer cell line derived from A2780 , OVCAR4, OVCAR5, and OVCAR10. SKOV3 cells were cultured in McCoy's 5A medium supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. C200, OVCAR4, OVCAR5, and OVCAR10 were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. HEK293 cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. All cultures were maintained at 371C in a humidified incubator containing 5% CO 2 . For certain experiments, cells were starved in serum-free medium for 20 h prior to treatment. C75 was purchased from Alexis Biochemicals (San Diego, CA, USA); LY294002 and cerulenin were purchased from Calbiochem (San Diego, CA, USA).
Generation of PTEN-inducible cell line IT-3015
A Tet-On gene expression system (BD Biosciences Clontech, Palo Alto, CA, USA) was used to establish the IT-3015 cell line. First, the PTEN-null Ishikawa cells were transfected with the pTet-on regulation vector. Stable transfectants were screened by culturing with 500 mg/ml G418. The cloned G418-resistant cells (IT-30) were then infected with pREVTRE2hyg-PTEN. To this end, the PT67 packaging cell line was transfected with the pRev-TRE retrovirus vector in which the murine mammary tumor virus promoter drives a hygromycin resistance gene and the Tet-sensitive promoter (Tet response element upstream of the minimal CMV IE promoter) regulates the inserted PTEN. Stable transfectants were screened with 250 mg/ml hygromycin B. The cloned G418-resistant and hygromycin B-resistant cells were screened for expression of PTEN. After screening, cells were cultured in Dulbecco's modified Eagle's medium with 10% FBS containing 100 mg/ml G418 and 100 mg/ml hygromycin B.
siRNA transfection AKT1 siRNA SMART TM pool and a nonspecific control pool were purchased from DHARMACON Research Inc. (Lafayette, CO, USA). At 1 day before transfection, HEK293 cells were seeded in six-well plates and incubated in DMEM supplemented with 10% FBS without antibiotics. Cells at 90% confluency were transfected with AKT1 siRNA or nonspecific siRNA according to the manufacturer's instructions. Briefly, 1 ml of Opti-MEM I reduced serum medium containing 200 nmol AKT1 siRNA SMART pool and 20 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was added to each well. After incubating the cells for 15 h, the lipid and siRNA complex was removed, fresh growth medium was added, and the cells were collected at 60 h post-transfection. Whole cell lysates were prepared and Western blot analysis was carried out as described below.
Preparation of whole cell homogenates
After treatment, cells were washed once in PBS and then scraped into whole cell lysis buffer (25 mM Hepes, pH 7.7, 75 mM NaCl, 2.5 mM MgCl 2 Á 6H 2 O, 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM DTT, 20 mM b-glycerophosphate) containing 1 Â complete protease inhibitors (Roche Molecular Biochemicals, Indianapolis, IN, USA), 1 mM PMSF, and phosphatase inhibitors Na 3 VO 4 (1 mM) and NaF (50 mM). Cell lysates were sonicated and centrifuged at 10 000 g for 20 min at 41C. Supernatants were used as whole cell extracts for Western blot analysis. Xenograft tumors were snap-frozen in liquid nitrogen and ground into powder, using a mortar and pestle, under frozen conditions. Whole cell lysis buffer was added to the powder, and the homogenates were sonicated and centrifuged at 10 000 g for 20 min at 41C. Supernatants were used as whole cell extracts for Western blot analysis. The concentration of protein was determined by Bio-Rad protein assay reagent using BSA as a standard.
Western blot analysis
Western blot analysis was carried out as described elsewhere (Wang and Smart, 1999) . Briefly, whole cell extract proteins (50-100 mg) were separated electrophoretically on 4-20% Novex Tris-glycine polyacrylamide gels (Invitrogen). Proteins were transferred to Immobilon TM -P membrane (Millipore Corporation, Bedford, MA, USA), blocked in 5% nonfat dry milk, 1% BSA, and 0.1% Tween 20. Membranes were probed with polyclonal antibody against phospho-AKT (serine 473) (Cell Signaling Technology, Beverly, MA, USA), polyclonal antibodies against total AKT and actin (Santa-Cruz Biotechnology, Santa Cruz, CA, USA), or a monoclonal FAS antibody (BD Transduction Laboratories, San Diego, CA, USA), polyclonal AKT1-specific antibody (Upstate, Lake Placid, NY, USA), polyclonal AKT2-specific antibody (Cell Signaling Technology). Immunoreactive bands were visualized by Western Lightning TM Chemiluminescence Reagent Plus (Perkin Elmer Life Science, Boston, MA, USA) and exposed to X-ray film. All experiments on Western blot analysis were performed three times.
Immunohistochemical analysis
An ovarian cancer tissue microarray was prepared by the Biosample and Tissue Procurement Core Facility at Fox Chase Cancer Center. Individual sections (4 mm thick) were deparaffinized and hydrated in water, followed by antigen retrieval in 10 mM citrate buffer, pH 6.0. Preparations were incubated in 3% H 2 O 2 for 20 min, washed with H 2 O or PBS, and blocked with 10% serum for 30 min. Polyclonal FAS antibody (Biotrend Chemical, Destin, FL, USA) was used at 5 mg/ml to detect the expression of FAS, and phospho-AKT (Ser473) antibody (Cell Signaling Technology) was used at a dilution of 1 : 50 to detect active forms of all three AKT isoforms. Primary antibodies were detected with biotinylated secondary antibody (BioGenex, San Ramon, CA, USA). The specificity of phospho-AKT (Ser473) antibody was demonstrated by preabsorbing the antibody with a phospho-AKT (Ser473) blocking peptide (Cell Signaling Technology). Tissue sections were stained with DAB chromagen and counterstained with hematoxylin. Surrounding non-neoplastic stroma served as an internal negative control for each slide. The slides were scored semiquantitatively. A score of 0 indicated no staining, 0.5 was generally negative with some focal staining, 1 was indicative of weak focal staining, 2 indicated clearly positive staining, and a score of 3 was intensely positive. We define scores of 2 or 3 as indicating elevated phospho-AKT staining. Tumors with weak or no staining were considered as negative for phospho-AKT and FAS. Both Fisher's exact test and Jonckheere-Terpstra test were used to analyse the correlation of phospho-AKT and FAS in these tumors.
Detection of apoptosis by ELISA
Cells were treated with cerulenin or C75 with or without LY294002 for 48 h. Cells were lysed using lysis buffer provided in the Cell Death Detection ELISA kit (Roche Molecular Biochemicals). Apoptosis was determined by measuring DNA fragmentation following the manufacturer's instructions.
In vivo xenograft model SCID mice were bred in-house at Fox Chase Cancer Center. The body weight of each mouse was monitored weekly. SKOV3 cells were injected into mice i.p. at 5 Â 10 6 in 200 ml PBS. After 1 week, mice were divided randomly into two treatment groups: control (n ¼ 6) and C75-treated (n ¼ 6) mice. Control mice received 5% DMSO in 200 ml of PBS i.p. weekly for 4 weeks. C75 at 20 mg/kg body weight was administered i.p. weekly for 4 weeks. At 3 days after the last treatment, mice were killed and the individual tumors were weighed and then snap-frozen in liquid nitrogen for storage. All animal experiments complied with institutional animal care guidelines.
Abbreviations FAS, fatty acid synthase; PI3K, phosphatidylinositol 3-OH kinase; SCID, severe combined immunodeficient.
